Idylla assay on extracted DNA: advantages, limits and place in molecular screening according to the latest guidelines for non-small-cell lung cancer (NSCLC) patients.
Fiche publication
Date publication
juillet 2022
Journal
Journal of clinical pathology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CHAPUSOT Caroline, Pr MARTIN Laurent
Tous les auteurs :
Khalifa E, Chapusot C, Tournier B, Sentis J, Marion E, Remond A, Aubry M, Pioche C, Bergeron A, Primois C, Blanchard L, Millière A, Boucheix M, Léger Y, Bairrao M, Brouste V, Martin L, Soubeyran I
Lien Pubmed
Résumé
Idylla epidermal growth factor receptor () is a fast and fully automated mutation assay that is easy to implement. However, under the Biocartis-recommended technical conditions, tissue sections are directly introduced into the cartridge, at the risk of exhausting the tumour sample. In this study, we evaluate the performance of Idylla on extracted DNA and discuss its place within the global non-small-cell lung cancer (NSCLC) screening strategy.
Mots clés
biomarkers, tumor, diagnostic screening programs, lung neoplasms, molecular biology, pathology, molecular
Référence
J Clin Pathol. 2022 07 12;: